In addition, we used a cohort of metastatic urothelial carcinomas (IMvigor210 cohort) that had actually received anti-PD-L1 immunotherapy to validate this result, and CD73 expression was indeed lower in the group that responded to immunotherapy (P = 0.0025) (Figure 4G). Here, NT5E is linked to urothelial carcinoma.